These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31707202)

  • 21. Sanger and Next Generation Sequencing Approaches to Evaluate HIV-1 Virus in Blood Compartments.
    Arias A; López P; Sánchez R; Yamamura Y; Rivera-Amill V
    Int J Environ Res Public Health; 2018 Aug; 15(8):. PubMed ID: 30096879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. External Quality Assessment for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Unique Requirements and Challenges.
    Lee ER; Gao F; Sandstrom P; Ji H
    Viruses; 2020 May; 12(5):. PubMed ID: 32429382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human immunodeficiency virus type 1 drug resistance testing: Evaluation of a new ultra-deep sequencing-based protocol and comparison with the TRUGENE HIV-1 Genotyping Kit.
    Stelzl E; Pröll J; Bizon B; Niklas N; Danzer M; Hackl C; Stabentheiner S; Gabriel C; Kessler HH
    J Virol Methods; 2011 Dec; 178(1-2):94-7. PubMed ID: 21907239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance.
    Pattery T; Verlinden Y; De Wolf H; Nauwelaers D; Van Baelen K; Van Houtte M; Mc Kenna P; Villacian J
    Intervirology; 2012; 55(2):138-46. PubMed ID: 22286884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison between next-generation and Sanger-based sequencing for the detection of transmitted drug-resistance mutations among recently infected HIV-1 patients in Israel, 2000-2014.
    Moscona R; Ram D; Wax M; Bucris E; Levy I; Mendelson E; Mor O
    J Int AIDS Soc; 2017 Aug; 20(1):21846. PubMed ID: 28799325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MinVar: A rapid and versatile tool for HIV-1 drug resistance genotyping by deep sequencing.
    Huber M; Metzner KJ; Geissberger FD; Shah C; Leemann C; Klimkait T; Böni J; Trkola A; Zagordi O
    J Virol Methods; 2017 Feb; 240():7-13. PubMed ID: 27867045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
    Saracino A; Gianotti N; Marangi M; Cibelli DC; Galli A; Punzi G; Monno L; Lazzarin A; Angarano G;
    J Med Virol; 2008 Oct; 80(10):1695-706. PubMed ID: 18712823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping.
    Parkin NT; Avila-Rios S; Bibby DF; Brumme CJ; Eshleman SH; Harrigan PR; Howison M; Hunt G; Ji H; Kantor R; Ledwaba J; Lee ER; Matías-Florentino M; Mbisa JL; Noguera-Julian M; Paredes R; Rivera-Amill V; Swanstrom R; Zaccaro DJ; Zhang Y; Zhou S; Jennings C
    Viruses; 2020 Jun; 12(7):. PubMed ID: 32605062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir + lamivudine in the maintenance DOLULAM pilot study.
    Charpentier C; Montes B; Perrier M; Meftah N; Reynes J
    J Antimicrob Chemother; 2017 Oct; 72(10):2831-2836. PubMed ID: 29091218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV-1 Drug Resistance Assay Using Ion Torrent Next Generation Sequencing and On-Instrument End-to-End Analysis Software.
    Pyne MT; Simmon KE; Mallory MA; Hymas WC; Stevenson J; Barker AP; Hillyard DR
    J Clin Microbiol; 2022 Jul; 60(7):e0025322. PubMed ID: 35699434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure.
    Fernández-Caballero JÁ; Chueca N; Álvarez M; Mérida MD; López J; Sánchez JA; Vinuesa D; Martínez MÁ; Hernández J; García F
    BMC Infect Dis; 2016 May; 16():197. PubMed ID: 27177767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 genotyping of the protease-reverse transcriptase and integrase genes to detect mutations that confer antiretroviral resistance.
    Van den Eede P; Van Wesenbeeck L; Verlinden Y; Feyaerts M; Smits V; Verheyen A; Vanhooren L; Deloof A; Villacian J; Pattery T
    Methods Mol Biol; 2013; 1030():37-55. PubMed ID: 23821259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Next generation sequencing based in-house HIV genotyping method: validation report.
    Ayitewala A; Ssewanyana I; Kiyaga C
    AIDS Res Ther; 2021 Oct; 18(1):64. PubMed ID: 34600538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proviral DNA as a Target for HIV-1 Resistance Analysis.
    Lübke N; Di Cristanziano V; Sierra S; Knops E; Schülter E; Jensen B; Oette M; Lengauer T; Kaiser R
    Intervirology; 2015; 58(3):184-9. PubMed ID: 26139571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of HIV-1 drug-resistance genotyping by ultra-deep sequencing and sanger sequencing using clinical samples.
    Trabaud MA; Icard V; Ramière C; Tardy JC; Scholtes C; André P
    J Med Virol; 2017 Nov; 89(11):1912-1919. PubMed ID: 28590068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.
    Dudley DM; Bailey AL; Mehta SH; Hughes AL; Kirk GD; Westergaard RP; O'Connor DH
    Retrovirology; 2014 Dec; 11():122. PubMed ID: 25533166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
    Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
    J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A MiSeq-HyDRA platform for enhanced HIV drug resistance genotyping and surveillance.
    Taylor T; Lee ER; Nykoluk M; Enns E; Liang B; Capina R; Gauthier MK; Domselaar GV; Sandstrom P; Brooks J; Ji H
    Sci Rep; 2019 Jun; 9(1):8970. PubMed ID: 31222149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.
    Geretti AM; Conibear T; Hill A; Johnson JA; Tambuyzer L; Thys K; Vingerhoets J; Van Delft Y;
    J Antimicrob Chemother; 2014 Apr; 69(4):1090-7. PubMed ID: 24284781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Shall I trust the report? Variable performance of Sanger sequencing revealed by deep sequencing on HIV drug resistance mutation detection.
    Chen NY; Kao SW; Liu ZH; Wu TS; Tsai CL; Lin HH; Wong WW; Chang YY; Chen SS; Ku SW
    Int J Infect Dis; 2020 Apr; 93():182-191. PubMed ID: 32061862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.